OHDSI Ireland

The all-island Irish National Node aims to be a forum to engage stakeholders and develop real world evidence data generation, data analytics to advance research, inform policy and improve health care outcomes.

Objectives 

The new OHDSI Ireland node would be established with the following goals and objectives:

• Facilitate collaboration and knowledge sharing, fostering real world evidence research on the island of Ireland
• Align with national health initiatives and stimulate research collaborations and projects on the island of Ireland, with European and global OHDSI partners
• Communicate OHDSI activities and facilitate engagement with OHDSI activities, meetings and events

To achieve these goals, the Irish National Node will focus on the following activities:

• Actively communicate OHDSI activities to stakeholders, to include academia, healthcare organizations, policy makers, eHealth enterprises, pharmaceutical companies, and clinical research institutions
• Engage regularly in OHDSI activities at the European level
• Establish a working group for RWE experts in the large Irish pharmaceutical sector to be part of the OHDSI community to increase industry engagement with OHDSI 

Node Members

Leading Organization

The leading organisation for the Irish National Node is the eHealth-Hub for Cancer (https://www.ehealth4cancer.ie), an All-Island partnership, led by Prof Aedin Culhane, University of Limerick and Prof Mark Lawler, Queen's University Belfast that brings together cancer researchers from 7 universities and 8 academic teaching hospitals. The eHealth-Hub for Cancer consortium are united in a common vision, to build partnerships north and south so that health-relevant data can be efficiently utilized to better understand cancer and to use this knowledge to fuel discovery in the diagnosis and treatment of this common disease, delivering research with clinical and societal impact and the potential to drive policy change.

The node is also supported by Eli Lilly and Company, who have been operating in Ireland since 1978 and have recently established pharmacoepidemiology, statistics, and health outcomes teams in their Cork site. Dr Catherine Mahoney is leading Lilly’s effort to engage with OHDSI and the OMOP-CDM to expand and improve the use of real-world evidence in patient care and drug development.

Members

The Irish National Node consists of representatives from organizations, including:

• Universities and research institutions
• Public and private hospitals
• Health technology companies
• Pharmaceutical companies
• Government health agencies

 Data Partners

The Irish National Node is working to establish partnerships and develop OMOP data resources to include:

• Hospitals on the Island of Ireland (public and private)
• Primary care networks
• National health registries
• Biobanks and research cohorts

Publications

Publications (OHDSI studies and related):

• Riba M, Sala C, Culhane AC, Flobak Å, Patocs A, Boye K, Plevova K, Pospíšilová Š, Gandolfi G, Morelli MJ, Bucci G, Edsjö A, Lassen U, Al-Shahrour F, Lopez-Bigas N, Hovland R, Cuppen E, Valencia A, Poirel HA, Rosenquist R, Scollen S, Arenas Marquez J, Belien J, De Nicolo A, De Maria R, Torrents D, Tonon G. The 1+Million Genomes Minimal Dataset for Cancer. Nat Genet. 2024 56(5):733-736. doi: 10.1038/s41588-024-01721-x. PMID: 38702538.
• Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrahão MTF, Alberga A, Alghoul H, Alser O, Alshammari TM, Aragon M, Areia C, Banda JM, Cho J, Culhane AC, Davydov A, DeFalco FJ, Duarte-Salles T, DuVall S, Falconer T, Fernandez- Bertolin S, Gao W, Golozar A, Hardin J, Hripcsak G, Huser V, Jeon H, Jing Y, Jung CY, Kaas-Hansen BS, Kaduk D, Kent S, Kim Y, Kolovos S, Lane JCE, Lee H, Lynch KE, Makadia R, Matheny ME, Mehta PP, Morales DR, Natarajan K, Nyberg F, Ostropolets A, Park RW, Park J, Posada JD, Prats-Uribe A, Rao G, Reich C, Rho Y, Rijnbeek P, Schilling LM, Schuemie M, Shah NH, Shoaibi A, Song S, Spotnitz M, Suchard MA, Swerdel JN, Vizcaya D, Volpe S, Wen H, Williams AE, Yimer BB, Zhang L, Zhuk O, Prieto-Alhambra D, Ryan P. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun. 2020 11(1):5009. doi: 10.1038/s41467-020-18849-z. PMID: 33024121; PMCID: PMC7538555.
  
  
• Roel E, Pistillo A, Recalde M, Sena AG, Fernández-Bertolín S, Aragón M, Puente D, Ahmed WU, Alghoul H, Alser O, Alshammari TM, Areia C, Blacketer C, Carter W, Casajust P, Culhane AC, Dawoud D, DeFalco F, DuVall SL, Falconer T, Golozar A, Gong M, Hester L, Hripcsak G, Tan EH, Jeon H, Jonnagaddala J, Lai LYH, Lynch KE, Matheny ME, Morales DR, Natarajan K, Nyberg F, Ostropolets A, Posada JD, Prats-Uribe A, Reich CG, Rivera DR, Schilling LM, Soerjomataram I, Shah K, Shah NH, Shen Y, Spotniz M, Subbian V, Suchard MA, Trama A, Zhang L, Zhang Y, Ryan PB, Prieto-Alhambra D, Kostka K, Duarte-Salles T. Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain. Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1884-1894. doi: 10.1158/1055-9965.EPI-21-0266. PMID: 34272262; PMCID: PMC8974356.
  
  
•  Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, Alser O, Alshammari TM, Biedermann P, Banda JM, Burn E, Casajust P, Conover MM, Culhane AC, Davydov A, DuVall SL, Dymshyts D, Fernandez-Bertolin S, Fišter K, Hardin J, Hester L, Hripcsak G, Kaas-Hansen BS, Kent S, Khosla S, Kolovos S, Lambert CG, van der Lei J, Lynch KE, Makadia R, Margulis AV, Matheny ME, Mehta P, Morales DR, Morgan-Stewart H, Mosseveld M, Newby D, Nyberg F, Ostropolets A, Park RW, Prats-Uribe A, Rao GA, Reich C, Reps J, Rijnbeek P, Sathappan SMK, Schuemie M, Seager S, Sena AG, Shoaibi A, Spotnitz M, Suchard MA, Torre CO, Vizcaya D, Wen H, de Wilde M, Xie J, You SC, Zhang L, Zhuk O, Ryan P, Prieto- Alhambra D; OHDSI-COVID-19 consortium. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol. 2020 Nov;2(11):e698-e711. doi: 10.1016/S2665-9913(20)30276-9. PMID: 32864627; PMCID: PMC7442425.
  
  
• Couespel N, Venegoni E, Lawler M The European Cancer Pulse: tracking inequalities in cancer control for citizen benefit. Lancet Oncol. 2023 May;24(5):441-442. doi: 10.1016/S1470-2045(23)00140-7.PMID: 37142370
  
  
• Lawler M, Davies L, Oberst S, Oliver K, Eggermont A, Schmutz A, La Vecchia C, Allemani C, Lievens Y, Naredi P, Cufer T, Aggarwal A, Aapro M, Apostolidis K, Baird AM, Cardoso F, Charalambous A, Coleman MP, Costa A, Crul M, Dégi CL, Di Nicolantonio F, Erdem S, Geanta M, Geissler J, Jassem J, Jagielska B, Jonsson B, Kelly D, Kelm O, Kolarova T, Kutluk T, Lewison G, Meunier F, Pelouchova J, Philip T, Price R, Rau B, Rubio IT, Selby P, Južnič Sotlar M, Spurrier-Bernard G, van Hoeve JC, Vrdoljak E, Westerhuis W, Wojciechowska U, Sullivan R European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission Lancet Oncol. 2023 Jan;24(1):e11-e56. doi: 10.1016/S1470-2045(22)00540-X. Epub 2022 Nov 16. PMID: 3640010
  
  
• Nolte E, Morris M, Landon S, McKee M, Seguin M, Butler J, Lawler M. Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries. Lancet Oncol. 2022 Nov;23(11):e502-e514. doi: 10.1016/S1470-2045(22)00450-8. PMID: 36328024

How to contribute?

You can find the latest information about the OHDSI all-island Ireland node on the eHealth-Hub website, or email at: This email address is being protected from spambots. You need JavaScript enabled to view it.

Join the OHDSI MSTeams community and subscribe to OHDSI working groups